| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.79 [0.48, 1.32] | | < 1 | | 76% | 2 studies (2/-) | 81.3 % | low | not evaluable | high | crucial | - |
| deaths (OS) (extension) | 0.63 [0.52, 0.76] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.53 [0.44, 0.64] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.81 [0.41, 1.61] | | < 1 | | 92% | 2 studies (2/-) | 72.4 % | some concern | not evaluable | moderate | important | - |
| DCR | 0.91 [0.63, 1.32] | | > 1 | | 0% | 1 study (1/-) | 31.6 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 1.60 [0.37, 6.89] | | > 1 | | 95% | 2 studies (2/-) | 73.6 % | some concern | not evaluable | moderate | non important | - |
| objective responses (ORR) (extension) | 3.54 [2.46, 5.10] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (any grade) | 14.27 [3.34, 61.03] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 4.03 [2.70, 6.00] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 1.39 [0.43, 4.44] | | < 1 | | 0% | 1 study (1/-) | 29.1 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 1.01 [0.64, 1.59] | | < 1 | | 0% | 1 study (1/-) | 48.7 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 0.71 [0.49, 1.03] | | < 1 | | 0% | 1 study (1/-) | 96.5 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 0.99 [0.02, 50.24] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 0.72 [0.45, 1.13] | | < 1 | | 0% | 1 study (1/-) | 92.2 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 0.52 [0.31, 0.88] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.25 [0.01, 5.50] | | < 1 | | 0% | 1 study (1/-) | 80.8 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.99 [0.18, 22.10] | | < 1 | | 0% | 1 study (1/-) | 28.8 % | NA | not evaluable | | non important | - |
| Arthralgia TRAE (grade 3-4) | 1.99 [0.07, 59.55] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.50 [0.04, 5.49] | | < 1 | | 0% | 1 study (1/-) | 71.5 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 0.12 [0.03, 0.39] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Cough TRAE (grade 3-4) | 3.99 [0.18, 88.92] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.50 [0.02, 14.84] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.48 [0.21, 1.09] | | < 1 | | 0% | 1 study (1/-) | 96.0 % | NA | not evaluable | | non important | - |
| Dry skin TRAE (grade 3-4) | 0.99 [0.02, 50.24] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 1.99 [0.07, 59.55] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.99 [0.20, 4.96] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Headache TRAE (grade 3-4) | 0.50 [0.02, 14.84] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 0.99 [0.02, 50.24] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.99 [0.02, 50.24] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.20 [0.02, 1.69] | | < 1 | | 0% | 1 study (1/-) | 93.0 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.99 [0.02, 50.24] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Increase AST TRAE (grade 3-4) | 1.50 [0.25, 9.01] | | < 1 | | 0% | 1 study (1/-) | 33.1 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 0.79 [0.21, 2.98] | | < 1 | | 0% | 1 study (1/-) | 63.5 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 1.17 [0.53, 2.56] | | < 1 | | 0% | 1 study (1/-) | 35.1 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.99 [0.18, 22.10] | | < 1 | | 0% | 1 study (1/-) | 28.8 % | NA | not evaluable | | non important | - |
| Myalgia TRAE (grade 3-4) | 1.99 [0.07, 59.55] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.25 [0.01, 5.50] | | < 1 | | 0% | 1 study (1/-) | 80.8 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 0.99 [0.06, 15.96] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.99 [0.02, 50.24] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 0.99 [0.06, 15.96] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.50 [0.02, 14.84] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 0.20 [0.02, 1.69] | | < 1 | | 0% | 1 study (1/-) | 93.0 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.99 [0.02, 50.24] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Vitiligo TRAE (grade 3-4) | 1.99 [0.07, 59.55] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.99 [0.06, 15.96] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.50 [0.02, 14.84] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 0.98 [0.14, 7.03] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 1.74 [0.50, 6.04] | | < 1 | | 0% | 1 study (1/-) | 19.1 % | NA | not evaluable | | non important | - |
| Arthralgia AE (grade 3-4) | 0.98 [0.02, 49.71] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 1.74 [0.50, 6.04] | | < 1 | | 0% | 1 study (1/-) | 19.1 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.98 [0.02, 49.71] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 1.97 [0.07, 58.97] | | < 1 | | 0% | 1 study (1/-) | 35.0 % | NA | not evaluable | | non important | - |
| Dermatitis acneiform AE (grade 3-4) | 22.68 [1.32, 388.47] | | < 1 | | 0% | 1 study (1/-) | 1.7 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 4.44 [1.47, 13.42] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 1.65 [0.39, 7.00] | | < 1 | | 0% | 1 study (1/-) | 24.9 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 1.97 [0.07, 58.97] | | < 1 | | 0% | 1 study (1/-) | 35.0 % | NA | not evaluable | | non important | - |
| Hypertension AE (grade 3-4) | 1.77 [0.73, 4.30] | | < 1 | | 0% | 1 study (1/-) | 10.5 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 3.00 [0.60, 15.03] | | < 1 | | 0% | 1 study (1/-) | 9.1 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 1.99 [0.49, 8.06] | | < 1 | | 0% | 1 study (1/-) | 16.8 % | NA | not evaluable | | non important | - |
| Increased Lipase Level AE (grade 3-4) | 2.00 [0.59, 6.74] | | < 1 | | 0% | 1 study (1/-) | 13.2 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 10.02 [0.54, 184.60] | | < 1 | | 0% | 1 study (1/-) | 6.3 % | NA | not evaluable | | non important | - |
| Peripheral oedema AE (grade 3-4) | 0.98 [0.06, 15.80] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 0.98 [0.02, 49.71] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 6.03 [0.72, 50.50] | | < 1 | | 0% | 1 study (1/-) | 5.0 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 7.83 [1.77, 34.66] | | < 1 | | 0% | 1 study (1/-) | 0.3 % | NA | not evaluable | | non important | - |
| Rash maculopapular AE (grade 3-4) | 7.98 [0.42, 151.89] | | < 1 | | 0% | 1 study (1/-) | 8.6 % | NA | not evaluable | | non important | - |
| Sepsis AE (grade 3-4) | 12.08 [0.67, 217.70] | | < 1 | | 0% | 1 study (1/-) | 4.7 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 2.49 [0.48, 12.97] | | < 1 | | 0% | 1 study (1/-) | 14.0 % | NA | not evaluable | | non important | - |
